To maximize their impact, public health officials stress the need to administer RSV prevention products as early as possible in the season.

Efforts are ongoing to address barriers to access for these preventive measures, ensuring that every eligible infant receives protection against RSV.

Public health recommendations emphasize the importance of early vaccination during pregnancy and timely administration of nirsevimab to protect infants, particularly those born during the RSV season.

The MMWR study advocates for maternal vaccination and nirsevimab administration to shield infants from severe RSV disease, especially before peak transmission periods.

While the study suggests a positive impact of the new interventions, the exact percentage of infants benefiting from them remains unclear, complicating the assessment of their overall effectiveness.

The 2024-25 RSV season marked the widespread availability of maternal RSV vaccines and nirsevimab, aimed at preventing severe RSV disease among infants and young children.

The vaccine, Abrysvo, is administered to pregnant individuals during their third trimester, while the antibody injection, Beyfortus, is given to newborns at risk of severe illness, providing crucial immunity against RSV.

Recent studies indicate that 64% of eligible pregnant individuals received the RSV vaccine, and 70.1% of eligible newborns were administered nirsevimab, resulting in over 80% overall protection against RSV.

Analysis of data from 36,949 eligible infants revealed that 72% were immunized against RSV, showcasing the effectiveness of these preventive measures.

During the 2024-2025 RSV season, hospitalization rates among infants aged 0-7 months were significantly lower, with a 43% reduction in the RSV-Associated Hospitalization Surveillance Network compared to pooled rates from 2018-2020.

Excluding data from Houston, the reduction in RSV hospitalizations for this age group reached as high as 71%, highlighting the impact of the new interventions.

A study published in May 2025 confirmed nirsevimab's effectiveness in preventing RSV-related hospitalizations, utilizing observational data from five countries.